Baker Tilly Wealth Management LLC Acquires 1,165 Shares of AstraZeneca PLC (NASDAQ:AZN)

Baker Tilly Wealth Management LLC raised its stake in shares of AstraZeneca PLC (NASDAQ:AZN) by 14.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 9,465 shares of the company’s stock after acquiring an additional 1,165 shares during the quarter. Baker Tilly Wealth Management LLC’s holdings in AstraZeneca were worth $620,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Martin Investment Management LLC grew its holdings in AstraZeneca by 2.8% in the third quarter. Martin Investment Management LLC now owns 284,204 shares of the company’s stock worth $22,571,000 after purchasing an additional 7,615 shares during the last quarter. Integrated Advisors Network LLC grew its stake in AstraZeneca by 46.6% during the 3rd quarter. Integrated Advisors Network LLC now owns 43,610 shares of the company’s stock worth $3,398,000 after buying an additional 13,860 shares during the last quarter. Creative Planning boosted its holdings in AstraZeneca by 8.0% in the third quarter. Creative Planning now owns 224,751 shares of the company’s stock worth $17,510,000 after acquiring an additional 16,692 shares in the last quarter. Soros Fund Management LLC boosted its holdings in AstraZeneca by 8.2% in the third quarter. Soros Fund Management LLC now owns 2,652,771 shares of the company’s stock worth $206,677,000 after acquiring an additional 201,233 shares in the last quarter. Finally, Optas LLC increased its holdings in shares of AstraZeneca by 173.5% during the third quarter. Optas LLC now owns 15,570 shares of the company’s stock valued at $1,213,000 after acquiring an additional 9,877 shares in the last quarter. 20.35% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several analysts have weighed in on the stock. UBS Group raised shares of AstraZeneca from a “sell” rating to a “neutral” rating in a research report on Wednesday, November 20th. Deutsche Bank Aktiengesellschaft raised shares of AstraZeneca from a “sell” rating to a “hold” rating in a report on Wednesday, November 6th. Two research analysts have rated the stock with a hold rating, six have issued a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $89.75.

AstraZeneca Stock Performance

Shares of NASDAQ:AZN traded up $0.86 during midday trading on Friday, reaching $67.44. The company’s stock had a trading volume of 1,614,751 shares, compared to its average volume of 3,565,128. The company has a quick ratio of 0.71, a current ratio of 0.93 and a debt-to-equity ratio of 0.71. The stock has a fifty day moving average of $66.20 and a 200 day moving average of $75.01. AstraZeneca PLC has a twelve month low of $60.47 and a twelve month high of $87.68. The firm has a market capitalization of $209.11 billion, a PE ratio of 32.27, a P/E/G ratio of 1.19 and a beta of 0.46.

AstraZeneca (NASDAQ:AZN) last announced its quarterly earnings results on Tuesday, November 12th. The company reported $1.04 earnings per share for the quarter, topping the consensus estimate of $1.01 by $0.03. AstraZeneca had a return on equity of 30.01% and a net margin of 12.68%. The company had revenue of $13.57 billion for the quarter, compared to the consensus estimate of $13.08 billion. During the same period last year, the firm earned $0.87 EPS. The firm’s revenue for the quarter was up 18.0% compared to the same quarter last year. On average, equities analysts expect that AstraZeneca PLC will post 4.11 EPS for the current fiscal year.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.